Matches in Wikidata for { <http://www.wikidata.org/entity/Q61906943> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- Q61906943 description "assaig clínic" @default.
- Q61906943 description "clinical trial" @default.
- Q61906943 description "clinical trial" @default.
- Q61906943 description "clinical trial" @default.
- Q61906943 description "clinical trial" @default.
- Q61906943 description "ensaio clínico" @default.
- Q61906943 description "ensayo clínico" @default.
- Q61906943 description "ensayu clínicu" @default.
- Q61906943 description "essai clinique" @default.
- Q61906943 description "klinisch onderzoek" @default.
- Q61906943 description "клінічне випробування" @default.
- Q61906943 description "կլինիկական փորձարկում" @default.
- Q61906943 description "临床试验" @default.
- Q61906943 name "Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia" @default.
- Q61906943 type Item @default.
- Q61906943 label "Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia" @default.
- Q61906943 prefLabel "Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia" @default.
- Q61906943 P1050 Q61906943-F8483863-B5C8-47D6-A444-91491FC06657 @default.
- Q61906943 P1132 Q61906943-97CC2AC1-3353-4642-9884-3B9AF509CAC0 @default.
- Q61906943 P1476 Q61906943-A8ABEF36-3405-490B-940F-7A189C33BBA2 @default.
- Q61906943 P17 Q61906943-B4260041-CCC7-477B-917E-2E90CB56B045 @default.
- Q61906943 P2899 Q61906943-9AB7E4BA-1C6F-4AF6-9016-3DA51A525666 @default.
- Q61906943 P3098 Q61906943-A7AEBEC2-2566-4ECB-9786-6A27529598FC @default.
- Q61906943 P31 Q61906943-AD6BEB87-AFB0-45AA-AAAC-8212E979D06B @default.
- Q61906943 P4135 Q61906943-2A3FD2DF-EC77-468C-9578-C3DE1B73453F @default.
- Q61906943 P4844 Q61906943-8E36BE35-56A1-401A-BC26-6D2D2E5A4EFE @default.
- Q61906943 P4844 Q61906943-BCDB1620-E0CA-4E2C-81DD-7CE6A565858B @default.
- Q61906943 P4844 Q61906943-D5635B26-7F76-4088-B53D-621707F7BBBF @default.
- Q61906943 P580 Q61906943-8FA8D8FB-6402-4DAD-80D0-8BD61AD5B57D @default.
- Q61906943 P582 Q61906943-CEFA9622-42D9-4230-A078-2C604BB5791E @default.
- Q61906943 P6099 Q61906943-948065C4-D447-45C8-B646-E387A5B22FE2 @default.
- Q61906943 P6153 Q61906943-C2C0D540-52C2-442F-8556-B0D1B534D318 @default.
- Q61906943 P8005 Q61906943-19DDD1D3-05E6-4744-B084-EC4563DEF525 @default.
- Q61906943 P8363 Q61906943-A0BBBF34-A8AC-4636-8E85-E042C6A2EFB7 @default.
- Q61906943 P1050 Q29496 @default.
- Q61906943 P1132 "+25" @default.
- Q61906943 P1476 "A Single-arm, Single Center Phase II Trial of Bendamustine/Rituximab Induction Followed by Venetoclax and Rituximab Consolidation for the Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)" @default.
- Q61906943 P17 Q30 @default.
- Q61906943 P2899 "+18" @default.
- Q61906943 P3098 "NCT03609593" @default.
- Q61906943 P31 Q30612 @default.
- Q61906943 P4135 "+99" @default.
- Q61906943 P4844 Q23671272 @default.
- Q61906943 P4844 Q27272066 @default.
- Q61906943 P4844 Q412323 @default.
- Q61906943 P580 "2018-08-01T00:00:00Z" @default.
- Q61906943 P582 "2021-12-31T00:00:00Z" @default.
- Q61906943 P6099 Q42824440 @default.
- Q61906943 P6153 Q2415975 @default.
- Q61906943 P8005 Q76649708 @default.
- Q61906943 P8363 Q78089383 @default.